AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05398679
Drug: Cefaclor
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefaclor intravenous 2 gr/day
Trial: NCT05398679
Drug: Ciprofloxacin Tablets
RxNorm normalized name: Ciprofloxacin Tablets
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500-750 mg/12 hrs (maximum 3g x day)
Trial: NCT05398679
Drug: Ciprofloxacin Injection
RxNorm normalized name: ciprofloxacin Injection
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg/day maximum dose IV
Trial: NCT05398679
Drug: Dicloxacillin Oral Capsule
RxNorm normalized name: dicloxacillin Oral Capsule
DrugBank: Dicloxacillin (DB00485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g/8 hours (maximum 4 gr day)
Trial: NCT05398679
Drug: Dicloxacillin
RxNorm normalized name: Dicloxacillin
DrugBank: Dicloxacillin (DB00485)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g/8 hours (maximum 4 g x day) IV
Trial: NCT05398679
Drug: Fusidic Acid Only Product in Oral Dose Form
RxNorm normalized name: Fusidic acid only product in oral dose form
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,750g/12 hours (maximum 1,5 g x day)
Trial: NCT05398679
Drug: Fusidic Acid Only Product in Parenteral Dose Form
RxNorm normalized name: Fusidic acid only product in parenteral dose form
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,75 g/12 hours (maximum 1,5 g x day)
Trial: NCT05398679
Drug: Levofloxacin Oral Tablet
RxNorm normalized name: levofloxacin Oral Tablet
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g/12-24hours (maximum 1 g x day)
Trial: NCT05398679
Drug: Levofloxacin Injection
RxNorm normalized name: levofloxacin Injection
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g/12-24hours (maximum 1 g x day)
Trial: NCT05398679
Drug: Linezolid Oral Tablet
RxNorm normalized name: linezolid Oral Tablet
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,6 g/12 hours (maximum 1200 mg x day)
Trial: NCT05398679
Drug: Linezolid Injectable Product
RxNorm normalized name: linezolid Injectable Product
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,6 g/12 hours (maximum 1200 mg x day)
Trial: NCT05398679
Drug: Moxifloxacin tablet
RxNorm normalized name: Moxifloxacin Tablets
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,4 g/day (maximum 400 mg x day)
Trial: NCT05398679
Drug: Moxifloxacin Injectable Product
RxNorm normalized name: moxifloxacin Injectable Product
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,4 g/day (maximum 400 mg x day)
Trial: NCT05398679
Drug: Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]
RxNorm normalized name: sulfamethoxazole / trimethoprim Oral Tablet [Bactrim]
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
Trial: NCT05398679
Drug: Sulfamethoxazole / Trimethoprim Injectable Product
RxNorm normalized name: sulfamethoxazole / trimethoprim Injectable Product
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulfamethoxazole 1600 mg/trimethoprin 320 mg (maximum x day)
Trial: NCT05398679
Drug: Tedizolid Oral Tablet
RxNorm normalized name: tedizolid Oral Tablet
DrugBank: Tedizolid phosphate (DB09042)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg tedizolid (maximum x day)
Trial: NCT05398679
Drug: Tedizolid Injection
RxNorm normalized name: tedizolid Injection
DrugBank: Tedizolid phosphate (DB09042)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg (maximum x day)
Trial: NCT05398679
Drug: Amoxicillin Capsules
RxNorm normalized name: Amoxicillin Capsules
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gr/6 hours (4 g x day)
Trial: NCT05398679
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gr/6 hours (4 g x day) Intravenous
Trial: NCT05398679
Drug: Cefaclor Capsules
RxNorm normalized name: Cefaclor Capsules
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 gr/day
Trial: NCT05935761
Drug: Pregnenolone
RxNorm normalized name: Pregnenolone
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone dosing will begin at 500mg/day x 7 days, and will increase by 500mg each following week as tolerated (to a potential maximum dose 2000mg/day).
Trial: NCT05935761
Drug: DHEA
RxNorm normalized name: DHEA
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DHEA dosing will begin at 100mg/day x 7 days, and will increase by 100mg each following week as tolerated (to a potential maximum dose 400mg/day).
Trial: NCT04987320
Drug: Olpasiran
RxNorm normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06408181
Drug: Aspirin 162 mg
RxNorm normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Trial: NCT06408181
Drug: Aspirin 81mg
RxNorm normalized name: ASPIRIN 81MG CAP
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin is a nonsteroidal anti-inflammatory drug.
Trial: NCT05087992
Drug: BI 905711
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905711
Trial: NCT05087992
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab
Trial: NCT04266730
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered at 200 mg IV dose every three weeks. The subject may transition to 400 mg every six weeks if, after the first scan done after start of treatment, they have a partial response or better or after two scans with stable disease or better.
Trial: NCT05899010
Drug: Vaginal progesterone 600mg daily
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Trial: NCT05899010
Drug: Vaginal progesterone 800mg daily
RxNorm normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: If endometrial thickness (ETH) ≥7 mm and follicle dominance/ultrasound (US) signs of ovulation P levels are measured: if P ≤1.5 patients start LPS, else cycle is cancelled. If ETH \<7mm and no follicle dominance: estradiol dose is increased to 9mg/day and new US is performed up to 4 days after. If persistent thin endometrium after dose increase, cycle is cancelled. 24-48h pre ET, E2 and P are measured. in the morning, pre VMP dose, or at least 6h after last progesterone dose. If progesterone \<10ng/ml, additional 300mg daily oral micronized progesterone is administered on the day of the ET and maintained until 10 weeks pregnancy or up to menses or up to negative pregnancy test 10 days after ET. ET will be performed with available blastocysts 6 days after start of LPS. 3-5 days, after ET, a blood test for P measurement will be performed in the morning, before VMP dose, or at least 6h after last progesterone dose. 10 days after ET, the last P test will be done with pregnancy test.
Trial: NCT05302284
Drug: RC48-ADC
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg IV every 2 weeks
Trial: NCT05302284
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg/kg IV every 2 weeks
Trial: NCT05302284
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 IV infusion on Days 1 and 8 of every 3 week cycle
Trial: NCT05302284
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70mg/m2 IV infusion on Day 1 of every 3 week cycle
Trial: NCT05302284
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=4.5, IV infusion on Day 1 of every 3 week cycle
Trial: NCT01931085
Drug: Triclabendazole
RxNorm normalized name: TRICLABENDAZOLE
DrugBank: Triclabendazole (DB12245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triclabendazole (10 mg/kg body-weight as a single dose).
Trial: NCT05060263
Drug: HOT-1030
RxNorm normalized name: Hot pepper
DrugBank: Red pepper (DB14759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection
Trial: NCT04807192
Drug: CMP-001
RxNorm normalized name: Cmp-001 component cpg-a oligodeoxynucleotide tlr9 agonist
DrugBank: Vidutolimod (DB17500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 sequential administrations of CMP001 at Day 1 (SC), Day 5 (±1) (IT), Day 9 (±1) (IT) and Day 16 (±1) (IT)
Trial: NCT06551246
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to randomization.
Trial: NCT06551246
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to randomization.
Trial: NCT06468280
Drug: PD-1 Monoclonal Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 monoclonal antibody will be administered at a dosage of 200 mg via intravenous infusion, once every cycle, each cycle spanning three weeks. The specific PD-1 antibody used will be determined by the investigators based on clinical considerations. Potential options include Sintilimab, Toripalimab, Nivolumab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.
Trial: NCT05550558
Drug: Anlotinib + Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib PO plus Camrelizumab IV
Trial: NCT05758922
Drug: AZ-3102 (Dose 1)
RxNorm normalized name: AZ-3102
DrugBank: AZ-3102 (DB18502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT05758922
Drug: AZ-3102 (Dose 2)
RxNorm normalized name: AZ-3102
DrugBank: AZ-3102 (DB18502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT06111014
Drug: Latozinemab
RxNorm normalized name: Latozinemab
DrugBank: Latozinemab (DB16978)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
Trial: NCT05869955
Drug: CC-97540
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05869955
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05869955
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05106296
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Trial: NCT05106296
Drug: Indoximod
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoximod will be taken by mouth twice daily, throughout each treatment cycle.
Trial: NCT05106296
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
Trial: NCT06496568
Drug: Inavolisib
RxNorm normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive inavolisib, 9 milligram (mg), PO, QD on Days 1-21 of each 21-day cycle.
Trial: NCT06496568
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive atezolizumab, 1200 mg, as IV infusion Q3W on Day 1 of each 21-day cycle.
Trial: NCT05756764
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medication for weight loss
Trial: NCT05756764
Drug: Phentermine-Topiramate combination
RxNorm normalized name: phentermine / topiramate
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication for weight loss
Trial: NCT05756764
Drug: Phentermine
RxNorm normalized name: Phentermine
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication for weight loss
Trial: NCT05756764
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication for weight loss
Trial: NCT05756764
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication for weight loss
Trial: NCT05756764
Drug: Diethylpropion
RxNorm normalized name: Diethylpropion
DrugBank: Diethylpropion (DB00937)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication for weight loss
Trial: NCT05756764
Drug: Naltrexone/Bupropion
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication for weight loss
Trial: NCT05756764
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medication for weight loss
Trial: NCT05732194
Drug: ITI-333
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-333 oral solution
Trial: NCT05624749
Drug: ianalumab
RxNorm normalized name: Ianalumab
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab s.c. monthly
Trial: NCT05107674
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel IV
Trial: NCT06114940
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative: Toripalimab 240mg, IV on day 1 in a 3-week cycle. Preoperative Toripalimab contains 4-5 cycles.~Postoperative: Toripalimab 240mg, IV on day 1 of a 3-week cycle. Postoperative Toripalimab following surgery within 4 weeks for patients mentioned above in cohort 1, 2 and 3.
Trial: NCT06114940
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Preoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Preoperative Lenvatinib contains 4-5 cycles.~Postoperative: Lenvatinib 20 mg orally, QD in a 3-week cycle. Postoperative Lenvatinib following surgery within 4 weeks for patients in cohort 3.~Adjustment of dose: For patients with intolerable adverse reactions (CTCAE v5.0 grade 3 or grater), the dose could be reduced to 12mg for those who were suitable to continue taking the drug after systematic evaluation by the investigator. Patients who are assessed as intolerable and not suitable for continued medication will discontinue and undergo nephrectomy within 4 weeks.
Trial: NCT05321121
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedotomidine for Acute Pain Control in Patients with Multiple Rib Fractures
Trial: NCT04900818
Drug: TJ033721 (givastomig)
RxNorm normalized name: Givastomig
DrugBank: Givastomig (DB18618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
Trial: NCT04900818
Drug: TJ033721 (givastomig) , nivolumab, chemotherapy
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy
Trial: NCT05571969
Drug: 2X-121 and dovitinib
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose levels to be evaluated in Part 1 are:~Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose: 400 mg + evening dose: 400 mg); Cohort 3 1000 mg (morning dose: 400 mg + evening dose: 600 mg);~The dose levels to be evaluated in Part 2 are:~Cohort 1 2X-121 (MTD) + 300 mg dovitinib; Cohort 2 2X-121 (MTD) + 400 mg dovitinib; Cohort 3 2X-121 (MTD) + 500 mg dovitinib;
Trial: NCT06680817
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faricimab will be administered as per local clinical practice and local labeling.
Trial: NCT04759911
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06232577
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT06232577
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT04457687
Drug: Lorcaserin
RxNorm normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lorcaserin 10 milligram (mg) tablets orally.
Trial: NCT04603365
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04603365
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04031066
Drug: Velmanase Alfa
RxNorm normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion i.v. treatment
Trial: NCT06589778
Drug: SHR-A2102
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A2102: injection, 80mg/ bottle, intravenous drip
Trial: NCT06589778
Drug: Adebelimab (SHR-1316)
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip
Trial: NCT06589778
Drug: SHR-8068
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
Trial: NCT05526742
Drug: CKD-510 capsule (reference)
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of CKD-510 will be administered as oral capsule in a fasted state.
Trial: NCT06683950
Drug: Aflibercept 8mg
RxNorm normalized name: AFLIBERCEPT 8MG/0.07ML INJ,SOLN
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switching to intravitreal aflibercept 8mg in patients previously treated with faricimab or aflibercept 2mg.~The dosing schedule is as follows.~1. A single dose of 8mg aflibercept was administered to all patients~2. After treatment 1, follow-up observations were conducted at the same intervals as previous treatments. If complete fluid resolution (no evidence of SRF or IRF) is observed, an additional dose of 8mg aflibercept is administered, extending the dosing intervals by two weeks each time.~3. Up to three doses of 8mg aflibercept can be administered.~4. If, after the administration of 8mg aflibercept, follow-up observations reveal remaining SRF or IRF, the study concludes without additional dosing.
Trial: NCT06682156
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carfilzomib C1: 20mg/m2，D1-2; 27mg/m2，D8-9; 36mg/m2，D15-16 C2 and subsequent cycles: 36mg/m2。
Trial: NCT05723055
Drug: Axatilimab
RxNorm normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody (mAb) with high affinity against colony stimulating factor-1 receptor (CSF-1R).
Trial: NCT05723055
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a programmed death receptor-1 (PD-1)-blocking antibody
Trial: NCT04996498
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy
Trial: NCT06217952
Drug: SPL84
RxNorm normalized name: SPL84-23-1
DrugBank: SPL84-23-1 (DB18575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL84 solution for nebulization